You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MRD positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

AML, MDS Trial in Houston (Vibecotamab, Dexamethasone, Acetaminophen)

Recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
Sep 29, 2022

ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)

Recruiting
  • ALL
  • +2 more
  • Inotuzumab Ozogamicin
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 14, 2023

Colorectal Cancer Trial (mFOLFOXIRI, mFOLFOX6)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Jun 17, 2022

Acute Myeloid Leukemia, Measurable Disease Trial in Tianjin (Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Measurable Disease
  • Venetoclax, Azacitidine
  • Venetoclax, daunorubicin, cytarabine
  • Tianjin, Tianjin, China
    HBDH
Apr 28, 2022

Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

Recruiting
  • Mixed Phenotype Acute Leukemia (MPAL)
  • Measurable Residual Disease (MRD)
  • BLINCYTO (Blinatumomab)
  • Baltimore, Maryland
    Greenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022

Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia
  • KIT Mutation-Related Tumors
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Apr 7, 2023

B-ALL Trial in Hangzhou (ThisCART19A)

Recruiting
  • B-ALL
  • ThisCART19A
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 26, 2022

Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))

Withdrawn
  • Prophylactic HQP1351 Therapy
  • Third Generation TKI
  • HQP1351( Olverembatinib dimesylate)
  • Guanzhou, China
    Department of Hematology, Nanfang Hospital, Southern Medical Uni
Jan 16, 2023

MRD Test in Common Risk Stage II Colorectal Cancer

Not yet recruiting
  • Stage II Colorectal Cancer
  • MRD test
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Mar 29, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023

Colorectal Cancer Trial in Shanghai, Hangzhou, Ningbo (Capecitabine tablets, Oxaliplatin)

Not yet recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
  • +3 more
Jan 16, 2023

Significance of MRD After Surgery in Driver Gene-positive and

Enrolling by invitation
  • NSCLC MRD ctDNA
    • Shenzhen, China
      ShenzhenPH
    Jun 30, 2022

    Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

    Not yet recruiting
    • Ph+ ALL
    • +2 more
    • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital, Chinese Acade
    Oct 30, 2022

    Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Feb 1, 2023

    Survival in Adult MRD Positive Acute Lymphoblastic Leukemia

    Completed
    • Acute Lymphoblastic Leukemia
      • Brno, Czechia
      • +9 more
      Sep 12, 2022

      HER2-positive Breast Cancer Trial in Chuo-ku

      Recruiting
      • HER2-positive Breast Cancer
        • Chuo-ku, Tokyo, Japan
          National Cancer Center Hospital, Japan
        Jun 22, 2022

        Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute Trial in Charlotte, Seattle (Clofarabine,

        Terminated
        Has Results
        • Minimal Residual Disease
        • +2 more
        • Charlotte, North Carolina
        • +1 more
        Oct 4, 2021

        Colon Cancer Trial (mFOLFIRINOX-FOLFIRI intensified chemo, FOLFOX or CAPOX adjuvant chemo)

        Not yet recruiting
        • Colon Cancer
        • mFOLFIRINOX-FOLFIRI intensified chemotherapy
        • FOLFOX or CAPOX adjuvant chemotherapy
        • (no location specified)
        Sep 6, 2022

        Acute Myeloid Leukemia, Adult Trial in Germany (Midostaurin)

        Terminated
        • Acute Myeloid Leukemia, Adult
        • Chemnitz, Germany
        • +3 more
        Jan 20, 2022

        Acute Myeloid Leukemia Trial in Germany (FLYSYN)

        Completed
        • Acute Myeloid Leukemia
        • FLYSYN
        • Tuebingen, Baden-Wuerttemberg, Germany
        • +4 more
        Sep 27, 2021

        Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

        Not yet recruiting
        • Adenocarcinoma of Lung
        • Beijing, China
          Peking University People's Hospital
        Oct 3, 2021

        Hematologic Malignancy, Stem Cell Transplant Complications Trial in Hangzhou (Azacitidine in Combination With Venetoclax)

        Recruiting
        • Hematologic Malignancy
        • Stem Cell Transplant Complications
        • Azacitidine in Combination With Venetoclax
        • Hangzhou, Zhejiang, China
          The first Affiliated Hospital of Zhejiang University
        Mar 24, 2021